Lexicon Pharmaceuticals Inc. LXRX) on Tuesday reported a loss of $64.8 million in its third quarter. On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 18 cents.

The deal is a boost to Lexicon, because the company was unlikely to try to sell Inpefa outside of the U.S. on its own, according to Jefferies’ Tsai. Meanwhile, the drug fits into plans by ...

Piper Sandler and H.C. Wainwright have both maintained positive ratings for Lexicon, highlighting the potential of the company's drugs, particularly sotagliflozin. The firms are keenly awaiting ...

There was a mystique to the gigging musician wandering the big city in search of work, because this work was creative, improvisational, at times transcendent. Young people who came of age before the ...

As well as resurrecting some of the company’s most iconic products, Bill Putnum Jr also saw that the music industry was ... using plug-ins from Neve, Moog, Lexicon, Capitol Studios and more.

The Lexicon, owned in a joint venture between Schroders Capital and Legal & General Capital, has announced around 30,000sq ft of new retail lettings with Dunelm, Levi’s and Tesco Express all set to ...

Lexicon Pharmaceuticals , Inc. (NASDAQ:LXRX), a biopharmaceutical company, has entered into an exclusive licensing agreement with Viatris Inc (NASDAQ:VTRS). for the development and ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), with a price target of $10.00. The company’s shares ...

21 into the cultural lexicon since its release ... singing in the song's music video. In 1978, White offered songwriter Allee Willis the chance to co-write the band's next album, and Willis ...

Experience the eBook and the associated online resources on our new Higher Education website. The Cambridge Greek Lexicon is based upon principles differing from those of existing Greek lexica.

Lexicon's commitment to pioneering medicines through its Genome5000™ program is evident in its pipeline of drug candidates in various stages of development, targeting diseases such as neuropathic pain ...

Lexicon Pharmaceuticals , Inc. (NASDAQ:LXRX), a biopharmaceutical company, has entered into an exclusive licensing agreement with Viatris Inc (NASDAQ:VTRS). for the development and commercialization ...